View More Recent Stories

Nov 6, 2024 06:44AM Ultragenyx Pharma (RARE) PT Raised to $95 at H.C. Wainwright

Nov 6, 2024 05:58AM Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

Nov 5, 2024 04:14PM Ultragenyx Pharma (RARE) Tops Q3 EPS by 8c, provides guidance

Oct 7, 2024 08:03AM Ultragenyx Pharma (RARE) Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

Oct 4, 2024 05:54AM Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

Oct 3, 2024 04:31PM Ultragenyx Pharma (RARE) Provides Update on Stage 1 Cohorts in Phase 1/2/3 Cyprus2+ Study

Oct 1, 2024 07:51AM TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Sep 30, 2024 08:30AM JPMorgan refreshed its U.S. Analyst Focus List, adding these six stocks

Sep 25, 2024 11:00AM JPM just refreshed its US Analyst Focus List, adding these 5 stocks

Sep 17, 2024 02:00PM JPMorgan refreshed its U.S. Analyst Focus List and added these four names

Aug 1, 2024 05:34PM Ultragenyx Pharma (RARE) Tops Q2 EPS by 14c; offers guidance

Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time

Jul 17, 2024 04:05PM Ultragenyx Pharma (RARE) Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102

Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview

Jun 17, 2024 02:17PM TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Jun 12, 2024 04:45PM After-hours movers: Broadcom, Dave & Buster's, Oxford Industries, and more

Jun 12, 2024 04:05PM Ultragenyx Pharma (RARE) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 12, 2024 04:00PM Ultragenyx Pharma (RARE) to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A

Jun 12, 2024 08:12AM Ultragenyx Pharma (RARE), Mereo BioPharma (MREO) Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) i

View More Recent Stories